retatrutide ada 2025 results Highlights: A New Era for GLP-1 Therapies in Obesity and Diabetes Retatrutide Phase 3 Data Show

P., Trumbauer W., Martin J

JUNE 24, 2026 The most anticipated weight-loss drug in the world has not been approved anywhere

Eli Lilly will likely submit its application in late 2026

PlexusDx compounded semaglutide injection at $189/mo (or $149/mo on the 6-month plan) across commitment tiers represents a 7585% savings compared to uninsured retail prices for identical active ingredients prepared under pharmaceutical-grade compounding standards

In wild type mice, intragastric administration of DB, PTC or a mixture of bitter compounds slowed gastric emptying substantially (55), while oral administration of DB (1 mg/kg) ( Gentia scabra root extract (300 mg/kg

So far loving it